474 related articles for article (PubMed ID: 15634030)
1. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.
Fleischhack G; Jaehde U; Bode U
Clin Pharmacokinet; 2005; 44(1):1-31. PubMed ID: 15634030
[TBL] [Abstract][Full Text] [Related]
2. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosou rea hydrochloride.
Kochi M; Kuratsu J; Mihara Y; Takaki S; Seto H; Uemura S; Ushio Y
Neurosurgery; 1993 Nov; 33(5):817-23. PubMed ID: 8264878
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.
Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J
J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal chemotherapy with antineoplastic agents in children.
Ruggiero A; Conter V; Milani M; Biagi E; Lazzareschi I; Sparano P; Riccardi R
Paediatr Drugs; 2001; 3(4):237-46. PubMed ID: 11354696
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal administration of topotecan in nonhuman primates.
Blaney SM; Cole DE; Godwin K; Sung C; Poplack DG; Balis FM
Cancer Chemother Pharmacol; 1995; 36(2):121-4. PubMed ID: 7767947
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic approaches to the treatment of meningeal malignancy.
Blaney SM; Balis FM; Poplack DG
Oncology (Williston Park); 1991 May; 5(5):107-16; discussion 123, 127. PubMed ID: 1831994
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.
Slavc I; Schuller E; Czech T; Hainfellner JA; Seidl R; Dieckmann K
J Neurooncol; 1998; 38(2-3):213-8. PubMed ID: 9696374
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat.
Kooistra KL; Rodriguez M; Powis G
Cancer Res; 1989 Feb; 49(4):977-82. PubMed ID: 2912564
[TBL] [Abstract][Full Text] [Related]
10. [Intrathecal infusion of the antineoplastic agents for meningeal dissemination].
Hodozuka A; Hayashi Y; Annei R; Hiroshima S; Saito M; Orimoto R; Sato M; Tanaka T
Gan To Kagaku Ryoho; 2008 Jun; 35(6):900-5. PubMed ID: 18633217
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
Chamberlain MC; Kormanik P; Howell SB; Kim S
Arch Neurol; 1995 Sep; 52(9):912-7. PubMed ID: 7661730
[TBL] [Abstract][Full Text] [Related]
12. Current pharmacological treatment approaches to central nervous system leukaemia.
Blaney SM; Balis FM; Poplack DG
Drugs; 1991 May; 41(5):702-16. PubMed ID: 1712705
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors.
Morikawa N; Mori T; Kawashima H; Fujiki M; Abe T; Kaku T; Konisi Y; Takeyama M; Hori S
Eur J Clin Pharmacol; 1998 Jul; 54(5):415-20. PubMed ID: 9754986
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system pharmacology of antileukemic drugs.
Balis FM; Poplack DG
Am J Pediatr Hematol Oncol; 1989; 11(1):74-86. PubMed ID: 2496615
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.
Berg SL; Balis FM; Zimm S; Murphy RF; Holcenberg J; Sato J; Reaman G; Steinherz P; Gillespie A; Doherty K
J Clin Oncol; 1992 Jan; 10(1):143-8. PubMed ID: 1727916
[TBL] [Abstract][Full Text] [Related]
16. Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
Salzer W; Widemann B; McCully C; Adamson PC; Balis FM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):235-40. PubMed ID: 11592346
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?
Siegal T
J Neurooncol; 1998; 38(2-3):151-7. PubMed ID: 9696366
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
Morikawa N; Mori T; Kawashima H; Takeyama M; Abe T; Kobayashi H
Biol Pharm Bull; 2001 Apr; 24(4):436-8. PubMed ID: 11305611
[TBL] [Abstract][Full Text] [Related]
19. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases.
Chamberlain MC; Kormanik PA; Barba D
J Neurosurg; 1997 Nov; 87(5):694-9. PubMed ID: 9347977
[TBL] [Abstract][Full Text] [Related]
20. Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
Kim S; Chatelut E; Kim JC; Howell SB; Cates C; Kormanik PA; Chamberlain MC
J Clin Oncol; 1993 Nov; 11(11):2186-93. PubMed ID: 8229133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
